5T1T

Irak4 kinase - compound 1 co-structure


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.34 Å
  • R-Value Free: 0.228 
  • R-Value Work: 0.206 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.

Smith, G.F.Altman, M.D.Andresen, B.Baker, J.Brubaker, J.D.Chen, H.Chen, Y.Childers, M.Donofrio, A.Ferguson, H.Fischer, C.Fischmann, T.O.Gibeau, C.Hicks, A.Jin, S.Kattar, S.Kleinschek, M.A.Leccese, E.Lesburg, C.Li, C.Lim, J.Liu, D.Maclean, J.K.F.Mansoor, F.Moy, L.Y.Mulrooney, E.F.Necheva, A.S.Presland, J.Rakhilina, L.Yang, R.Torres, L.Zhang-Hoover, J.Northrup, A.

(2017) Bioorg. Med. Chem. Lett. 27: 2721-2726

  • DOI: 10.1016/j.bmcl.2017.04.050
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Interleukin-1 receptor associated kinase 4 (IRAK4) has been implicated in IL-1R and TLR based signaling. Therefore selective inhibition of the kinase activity of this protein represents an attractive target for the treatment of inflammatory diseases. ...

    Interleukin-1 receptor associated kinase 4 (IRAK4) has been implicated in IL-1R and TLR based signaling. Therefore selective inhibition of the kinase activity of this protein represents an attractive target for the treatment of inflammatory diseases. Medicinal chemistry optimization of high throughput screening (HTS) hits with the help of structure based drug design led to the identification of orally-bioavailable quinazoline based IRAK4 inhibitors with excellent pharmacokinetic profile and kinase selectivity. These highly selective IRAK4 compounds show activity in vivo via oral dosing in a TLR7 driven model of inflammation.


    Organizational Affiliation

    Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, United States.,Blueprint Medicines, 38 Sidney St Suite 200, Cambridge, MA 02139, United States.,Oncorus, 50 Hampshire St. Suite 401, Cambridge, MA 02139, United States.,Theravance Biopharma US, Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, United States.,Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, United States. Electronic address: jongwon_lim@merck.com.,Redx Pharma, Block 33, Mereside, Alderley Park, Macclesfield SK10 4TG, United Kingdom.,AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States. Electronic address: Graham.smith@astrazeneca.com.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Interleukin-1 receptor-associated kinase 4
A, B, C, D
301Homo sapiensMutation(s): 0 
Gene Names: IRAK4
EC: 2.7.11.1
Find proteins for Q9NWZ3 (Homo sapiens)
Go to Gene View: IRAK4
Go to UniProtKB:  Q9NWZ3
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
76P
Query on 76P

Download SDF File 
Download CCD File 
A, B, C, D
~{N},~{N}-dimethyl-4-(6-nitroquinazolin-4-yl)oxy-cyclohexan-1-amine
C16 H20 N4 O3
UCYLWJABRYZSHN-AULYBMBSSA-N
 Ligand Interaction
Modified Residues  2 Unique
IDChainsTypeFormula2D DiagramParent
SEP
Query on SEP
A, B, C, D
L-PEPTIDE LINKINGC3 H8 N O6 PSER
TPO
Query on TPO
A, B, C, D
L-PEPTIDE LINKINGC4 H10 N O6 PTHR
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
76PIC50: 58 nM BINDINGMOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.34 Å
  • R-Value Free: 0.228 
  • R-Value Work: 0.206 
  • Space Group: C 1 2 1
Unit Cell:
Length (Å)Angle (°)
a = 143.000α = 90.00
b = 139.560β = 124.45
c = 87.340γ = 90.00
Software Package:
Software NamePurpose
AutoPROCdata scaling
XDSdata reduction
BUSTERrefinement
SCALAdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2016-08-22 
  • Released Date: 2017-05-03 
  • Deposition Author(s): Fischmann, T.O.

Revision History 

  • Version 1.0: 2017-05-03
    Type: Initial release
  • Version 1.1: 2017-06-28
    Type: Database references
  • Version 1.2: 2017-11-22
    Type: Refinement description